FDA 483 - Genentech Inc - August 13, 2018

Genentech Inc. in Vacaville, CA, a drug substance manufacturer, received a Form 483 citing three significant observations. The inspection revealed deficiencies in label reconciliation procedures, inadequate documentation of cleaning and sanitizing materials for equipment, and insufficient computer controls to prevent manipulation or omission of electronic raw data, particularly for raw material testing.